Optimizing Outcomes in Bladder Cancer: Case Studies

Access Course


884786.jpg?interpolation=lanczos-none&resize=300:225Dr Petros Grivas explores the role of immunotherapy in advanced bladder cancer through a platinum-eligible and a platinum-ineligible patient.

This activity is intended for oncologists, urologists, surgeons, pharmacists, and other healthcare professionals who treat patients with bladder cancer.

The goal of this activity is to discuss the latest advances in the use of immunotherapy in patients with advanced bladder cancer.



Approximate Time to Complete: 30 minutes


Credit Available: Dec. 20, 2017-Dec. 20, 2018


Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the ongoing trials studying immune checkpoint inhibitors alone or in combination in the management of advanced bladder cancer
  • Have increased knowledge regarding the collaborative and individual roles of the healthcare team in the management of patients with advanced bladder cancer
  • Have greater competence related to selecting the most appropriate regimen for patients with advanced bladder cancer
  • Have greater competence related to recognizing immune-related adverse events in a patient with advanced bladder cancer
Accreditation Council For Continuing Medical Education
AMA PRA Category 1 Credit(s)™: 1.00
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 1.00
Accreditation Council for Pharmacy Education
CEU: 1.00